Regulatory Approval of Three Rapid Microbiological Methods for MACI® Product Release
Posted on January 9, 2019
John Duguid, Senior Director, Research & Development
James Birkhead, Associate Director of Process Development, Research & Development
Adam Barron, Associate Director, Research & Development
Vericel Corporation
Introduction Autologous cell therapy products are patient-specific therapies that utilize cells harvested from a single patient to treat that same patient. The patient-specific nature of these treatments mitigates potential safety concerns including viral contamination and immune response (rejection...
To read the full article and other articles in this issue, please register for a free account or log in.
We will not sell or give your information to a third party. See our Privacy Policy
Related Topics and Keywords
Autologous cell therapy products, cell therapy products, MACI®, Rapid Microbiological Methods
Subscribe to our FREE newsletter and WEBINAR UPDATES
We will not sell or give your information to a third party. See our Privacy Policy
